NCT00219726View on ClinicalTrials.gov

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2002

Study Completion Date

July 31, 2007

Conditions
Chronic Myeloid Leukemia
Interventions
DRUG

Imatinib mesylate

Trial Locations (1)

86021

University Hospital, Poitiers

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Poitiers University Hospital

OTHER

NCT00219726 - Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation | Biotech Hunter | Biotech Hunter